Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Biochemistry|February 23, 1988
Proteolytic studies on the structure of bovine von Willebrand factorM A Mascelli, E P KirbyPathology Oncology Research : POR|October 18, 2000
Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indicationsS A Cohen, M Trikha, M A MascelliThrombosis and Haemostasis|April 20, 2001
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofibanS J Marciniak, R E Jordan, M A MascelliBiochemistry|October 7, 1986
Characterization of a fragment of bovine von Willebrand factor that binds to plateletsM A Mascelli, T S Edgington, E P KirbyThe Journal of Laboratory and Clinical Medicine|July 1, 1987
Modification of the platelet-binding domain of von Willebrand factorC Silverman, M A Mascelli, D W Karl, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1991
Ig H and L chain contributions to autoimmune specificitiesM Z Radic, M A Mascelli, J Erikson, et al.Respiratory Medicine|August 13, 2008
Comparison of exhaled nitric oxide measurements between NIOX MINO electrochemical and Ecomedics chemiluminescence analyzerJ D Boot, L de Ridder, M L de Kam, et al.American Heart Journal|March 31, 2000
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximabM A Mascelli, N S Kleiman, S J Marciniak, et al.Circulation|May 20, 1998
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockadeM A Mascelli, E T Lance, L Damaraju, et al.Blood|August 1, 1996
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human plateletsC L Wagner, M A Mascelli, D S Neblock, et al.Pageof 3